omacetaxine mepesuccinate   Click here for help

GtoPdb Ligand ID: 7454

Synonyms: CGX-635 | HHT | homoharringtonine | Myelostat® | Synribo®
Approved drug PDB Ligand
omacetaxine mepesuccinate is an approved drug (FDA (2012))
Comment: Omacetaxine mepesuccinate is a semi-synthetic derivative of the alkaloid cephalotaxine from Cephalotaxus harringtonia. Note that this compound is represented on Drugbank with slightly different stereochemistry by the entry DB04865.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 123.99
Molecular weight 545.26
XLogP 1.72
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)CC(C(=O)OC1C(=CC23C1c1cc4OCOc4cc1CCN3CCC2)OC)(CCCC(O)(C)C)O
Isomeric SMILES COC(=O)C[C@@](C(=O)O[C@@H]1C(=C[C@]23[C@@H]1c1cc4OCOc4cc1CCN3CCC2)OC)(CCCC(O)(C)C)O
InChI InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1
InChI Key HYFHYPWGAURHIV-JFIAXGOJSA-N
No information available.
Summary of Clinical Use Click here for help
This drug was designated as an orphan drug for rare diseases by the European Medicines Agency (EMA) in 2004, for treatment of chronic myeloid leukemia (CML). In 2012, the US FDA granted full approval for the same indication, in patients who have shown resistance and/or intolerance to two or more tyrosine kinase inhibitors.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Omacetaxine inhibits protein translation. It is hypothesised that the drug binds to the A site of the 60S ribosomal subunit, preventing entry of charged tRNAs, thereby preventing elongation of nascent proteins [2,4]. The cells undergo cell cycle arrest [5] and apoptose [1].
External links Click here for help